April 27, 2016
A New Jersey federal judge on Tuesday again dismissed a securities class action against biopharmaceuticals maker Amarin claiming it failed to fully inform investors about its progress during a failed bid to obtain approval for the expanded use of its fish oil drug Vascepa, saying no identified statements were materially false or misleading.
July 02, 2015
A New Jersey federal judge has dismissed a securities class action against biopharmaceuticals maker Amarin Corp. PLC that claimed it artificially inflated its stock price before a U.S. Food and Drug Administration panel denied expanding the use of its fish oil drug Vascepa to treat more adults with high triglycerides.